Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

To examine the relation between haemodynamics and atrial natriuretic peptide concentration during short term angiotensin converting enzyme inhibition.

Who Took Part

According to the abstract, 38 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

38 Patients with stable congestive heart failure caused by ischaemic heart disease.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.

Cardiac units of two tertiary referral hospitals.

What Was Measured

The subject headings attached to it are Arginine Vasopressin, Atrial Natriuretic Factor, Heart Failure, Hemodynamics, Myocardial Ischemia, Peptidyl-Dipeptidase A and Pulmonary Wedge Pressure.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 38 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (British heart journal), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.